Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

RESPOND logo with the wording 'Rescue for Emergency Surgery Patients Observed to uNdergo acute Deterioration'
'Funded by' National Institute for Health and Care Research (NIHR) logo

Please see the “For RESPOND Leaders” tab for an overview of what data is collected and how the Audit data collection relates to the Trial data collection. 

Collaborative members will have full authorship rights on the publications describing the outcomes of this unique study. To earn these, members will need to:

  1. Collect data for the Audit 
  2. Supervise the screening and consent processes carried out by Research Nurses once the trial begins  
  3. Promote the study and the use of its component parts within their Unit.  

Trainees will be eligible for authorship if they participate in these activities for at least three months and can show that recruitment and data collection were maintained at expected levels during this time. Please see more about the Rules of the Collaborative

If you are interested in joining the Collaborative, please register this interest with us by completing the online form. Please note that you can only collect data for the Collaborative if your site is a registered RESPOND site. The form will ask you to indicate your Trust and we will let you know if your Trust is not a RESPOND site. Therefore, you can join the Collaborative if you are working at a RESPOND site now or know that you will be doing so within the next 2.5 years.  

The Collaborative is led by Mr Riadh Salem, ST5, with support from Professor Peter McCulloch, at the University of Oxford, who is the Chief Investigator for the RESPOND trial. Please reach out with questions.